Feeds:
Posts
Comments

Posts Tagged ‘Wyeth’

*****

TODAY’S NEWS:

Very big news for Vertex75% of hepatitis C patients never treated before achieved a viral cure after receiving a 12-week course of the company’s experimental drug telaprevir plus the current standard of care, according to results from a phase III studymore

Genzyme’s Pompe remedy approved by FDA; meanwhile, more detail on their consent decree.

More on alleged Wyeth tactics to promote Rapamune off-label. If true, yuck! Gold-in Rule at work.

Connecticut passes new pharma ethics code.

Part 2 of my interview over at MessagingLab blog (by Karl Schmieder): Pharma, Social Media, and the FDA.

RECOMMENDED

Coaching skills. Your field managers and other leaders are constantly in need of improvement here.  And we have great partners to recommend for coaching programs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media in Pharma stuff today: An “Ultimate Guide to Facebook“, from our friends over at Pixels and Pills. And, reporting adverse events on social media. More? Sure – comparing how pharma companies are using social media currently (from @healthcarengage). Even more? OK, you asked for it – Social Media and Celebrities in pharma (from John Mack’s blog)

JUST FOR FUN

Examples of Lightning Photography. Stunningly beautiful.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS:

Watson gets FDA approval to start shipping generic Valtrex.

Novartis oral MS drug – FDA extends review another 3 months – Novartis will have to wait a bit longer in its bid to get the first oral treatment for multiple sclerosis on the market after regulators in the USA put back a review of Gilenia. The US Food and Drug Administration has extended by three months, to September, its review period for Gilenia (fingolimod), previously known as FTY720more

Genzyme: Big fine, big changes to get manufacturing back under control.

Another day, another whistleblower suit comes to light. This time, Wyeth and Rapamune promotion for unapproved uses.

Layoffs at Quintiles.

RECOMMENDED

Train-the-Trainer. Your new trainers have whole new sets of skills (curriculum design, ISD, project management, presentation, etc.) – we have great partners to recommend. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

The Three “I’s” of Tomorrow’s Successful Company. An important perspective from Dennis Urbaniak (VP U.S. Diabetes, Sanofi-Aventis). Titles, Budgets, and Staff are out – Ideas, Initiative, and Inspiration are in.

JUST FOR FUN

50 Beautiful Examples of Architecture Photography.———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Pfizer buying Wyeth. Merck buying Schering-Plough. It’s pharma mega-merger season again.

I hate it.

“Market conditions” | “Complementary pipelines” | “Operational synergies” blah, blah, blah. I’ve heard all the explanations and rationalizations dozens of times before.

Analysts are looking at numbers. I’m looking at faces.

Every one of these mergers has a huge price tag that is rarely weighed in the balance. It’s called disruption.

  • Really good people end up losing their jobs, simply because they are re-labeled from “contributor” to “redundant”.
  • Creative and promising initiatives are stopped dead in their tracks, and often taken out back for burial.
  • Healthy corporate cultures are destroyed.
  • Productivity nosedives for month after month, as no-one knows what (if) their job will be in the future, and the inevitable jockeying and posturing takes over.
  • Agencies and service providers that served one (or both) companies are thrown into a tizzy and lose large volumes of work.
  • Any residual notion of corporate loyalty in our professional arena erodes further, with subsequent resentment and disenchantment.

I remember, with fondness, rubbing shoulders with the folks at Parke-Davis, at RPR, at HMR, at Pharmacia, at Aventis, at Wyeth, at Takeda. I remember bright and motivated people, imaginative programs, interesting corporate cultures, strong professional relationships. And I remember the disruption with every merger or buyout.

Yes, yes, I know that some mergers may actually pan out with an upside down the road (certainly not always, however!). And, some folks get a big payday out of these events. But sweep aside all those numbers, and if you’re involved in the industry, you see people. And pain. I hate these mergers.

Reblog this post [with Zemanta]

Read Full Post »

Enormous Bextra charge taken by Pfizer - If you’re going to take a $2.3 billion earnings hit over government investigations, you might as well announce it the same day everybody’s more interested in your $68 billion deal.

Amid the hullaballoo over Pfizer’s bid for Wyeth today, Pfizer announced its fourth-quarter earnings, which fell to $266 million from $2.72 billion a year earlier, due primarily to that enormous charge. It stems from an agreement in principle that Pfizer made with the U.S. Attorney in Massachusetts to resolve probes over alleged off-label marketing of now-withdrawn painkiller Bextra, plus “other open investigations,” the company said.

Jim Edwards over at BNET explains how this settlement was both disclosed and “hidden.”

KV Pharmaceutical – major problems. KV Pharmaceutical (NYSE: KVa/KVb) has voluntarily suspended the manufacturing and shipping of all of its products, other than certain products that it distributes but does not manufacture. The suspension began on January 22, 2009.

Generic surge the major cause of drop in pharma sales forces? Sounds plausible, but where’s the data? Is this just a conclusion pulled out of thin air?

PLUS…blah blah blah Pfizer-Wyeth blah blah blah Wyeth-Pfizer… A lot of the coverage is endless repetition of not much. Here’s the take by some analysts, from the WSJ Health blog (a great source for pharma news, btw). And here’s a scary number – up to 25,000 job cuts?

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.

Reblog this post [with Zemanta]

Read Full Post »

Of course, the huge news this Monday morning…Pfizer buying Wyeth. This will dominate the headlines for days. Before the deal was announced, Jim Edwards did some analysis on potential downsides – interesting stuff. This also means that the Wyeth-Crucell discussions are scuttled. And who else may be making deals in the days ahead?

My take, fwiw – While lots of folks focus on the stock premium, the synergies of the product mix, the cost savings by chopping overlaps, etc., few talk about the incredible disruption that now occurs with both companies, as extraordinary amounts of time, attention, money, and other resources are expended coming up with merger plans and processes. There are the terrible work inefficiencies that occur every time one of these mega-mergers creeps forward, as initiatives are stalled, employees are paralyzed by angst as to their future roles, recruites swoop in and cherry-pick talent, etc. It gets really messy as entire organizations are unwound and PEOPLE are transitioned from clear productive direction to fear and uncertainty, over many months. It’s ugly. As a solutions-provider for many pharma clients over the years, I’ve seen this unpleasant process many times. My heart goes out to the folks at Wyeth, who now have to wrestle with loads of questions, and very few answers…

Here’s a list of the Top Ten (by $ value) pharma mergers in the past (a couple are “in process” currently).

The multiple sclerosis pill development race accelerates. Whatever the outcome of the 2-company race to market, these two experimental drugs promise to be a great win for patients. Merck KGaA pulled ahead of Novartis in the race to develop the first pill for multiple sclerosis on Friday, announcing it planned to submit its drug cladribine for approval in mid-2009.

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.

Reblog this post [with Zemanta]

Read Full Post »

The Sales Force Shuffle, from Pharmaceutical Executive – The last week the pharma atmosphere was abuzz with news about sales force cuts, outsourcing, and overhauls. First, Schering-Plough announced that it had eliminated the 1,000 sales positions it said it would trim in April. This is being done as part of a new sales model called—internally—a productivity transformation program (PTP). The new model, to go into effect next month, will streamline the sales force to take a more customer-centric approach, including targeted and relevant physician calls and a relationship management–oriented business model…more

Alpharma to King: No. – In a filing with the Securities and Exchange Commission, Alpharma calls the $37-a-share offer was inadequate and continues to explore all strategic alternatives, including a possible sale to King or another party for a higher price…more

Lilly CEO to Boston: you’re scaring us away – The ink is barely dry on a new law governing how drugmakers can market to docs, but Lilly’s John Lechleiter isn’t wasting time trying to make lawmakers regret their decision. In remarks to the Associated Industries of Massachusetts Executive Forum, he claims the law will hamper innovation and force companies to reconsider expanding in Massachusetts, The Boston Business Journal reports…more

B-I goes to the shrink – The drugmaker has ended a contract with InVentiv, one of the players in the Rent-A-Rep business, which was promoting its troubled Micardis, an angiotensin receptor blocker, otherwise known as a blood pressure med…more

The needle or the drug? – Acupuncture works as well as Wyeth’s antidepressant to fight hot flashes and other menopausal symptoms caused by breast cancer treatment, and its benefits last longer without causing unwanted side effects, according to new research…more

Pfizer’s Pfuture – The big drugmaker is dramatically stepping up sales efforts in emerging markets, overhauling US business operations and slashing more costs ahead of the 2011 patent loss for cholesterol blockbuster Lipitor, the Associated Press informs us…more Plus, going after emerging markets for growth

Paxil damages sperm? – A group of 35 healthy men who were given Paxil over a five-week period had higher levels of sperm with damaged DNA, according to a report..more

Medicis to re-state numbers; stock plunges.

Tarceva linked to liver damage - Genentech Inc and OSI Pharmaceuticals have alerted doctors about cases of liver damage among patients who took the cancer drug Tarceva in a post-approval study, U.S. regulators said on Tuesday…more

Takeda goes for diabetes combo – Takeda Pharmaceutical Co said on Wednesday it had applied for approval to market in the United States the SYR-322 and the Actos diabetes drugs in a single tablet for the treatment of type 2 diabetes…more

An interesting analysis on adverse event reporting, and social media.

Is the war on cancer really winnable? A realistic and pessimistic analysis from Newsweek.

Reblog this post [with Zemanta]

Read Full Post »

A long and interesting article from NY Times magazine, about the process a doctor went through as a “recruit” to be a paid spokesperson for a drug company.

Excerpt:

    How many doctors speak for drug companies? We don’t know for sure, but one recent study indicates that at least 25 percent of all doctors in the United States receive drug money for lecturing to physicians or for helping to market drugs in other ways. This meant that I was about to join some 200,000 American physicians who are being paid by companies to promote their drugs. I felt quite flattered to have been recruited, and I assumed that the rep had picked me because of some special personal or professional quality…Regardless of how I preferred to think of myself (an educator, a psychiatrist, a consultant), I was now classified as one facet of a lunch helping to pitch a drug, a convincing sidekick to help the sales rep. Eventually, with an internal wince, I began to introduce myself as “Dr. Carlat, here for the Wyeth lunch.”

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 29 other followers